Study of Pemetrexed and Carboplatin Compared With Etoposide Carboplatin to Treat Extensive-Stage Small Cell Lung Cancer
Status:
Completed
Trial end date:
2008-06-01
Target enrollment:
Participant gender:
Summary
This study is a Phase 3, global, multi-center, open-label study of patients with
extensive-stage small cell lung cancer. Eligible patients will be randomly assigned to
receive either pemetrexed plus carboplatin or etoposide plus carboplatin. It is anticipated
that pemetrexed plus carboplatin will offer similar survival benefits as compared to
etoposide plus carboplatin.